Stockscreener 앱 받기
0.5061
2.69%
-0.014
전일 마감가:
$0.52
열려 있는:
$0.52
하루 거래량:
166.00K
Relative Volume:
0.18
시가총액:
$16.91M
수익:
-
순이익/손실:
$-19.73M
주가수익비율:
-0.244
EPS:
-2.0742
순현금흐름:
$-16.94M
1주 성능:
-1.82%
1개월 성능:
-13.50%
6개월 성능:
-47.84%
1년 성능:
-29.39%
1일 변동 폭
$0.50
$0.52
1주일 범위
$0.50
$0.61
52주 변동 폭
$0.281
$2.06
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
명칭
Pasithea Therapeutics Corp
전화
(702) 514-4174
주소
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Compare KTTA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
0.5061 | 18.37M | 0 | -19.73M | -16.94M | -2.0742 |
VRTX
Vertex Pharmaceuticals Inc
|
525.47 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
670.90 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
926.20 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
317.14 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.90 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pasithea Therapeutics Corp 주식(KTTA)의 최신 뉴스
Coastlands holds 3.84M shares in Pasithea Therapeutics (KTTA) — 11.48% disclosed - Stock Titan
Pasithea Therapeutics Corp Warrant 2021-12.08.26 on Pasithea Therapeutics Financial Disclosures & SEC Filings - TradingView
Pasithea extends dose escalation for MEK inhibitor PAS-004 - Investing.com UK
Pasithea extends dose escalation for MEK inhibitor PAS-004 By Investing.com - Investing.com South Africa
Pasithea Therapeutics Corp. announced that its candidate drug Pas-4 demonstrated a favorable safety profile in clinical studies. - Bitget
Pasithea reports positive PAS-004 Phase 1 cancer data - grafa.com
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion - Investing News Network
Pasithea says PAS-004 stayed tolerable in cancer patients as dosing widens - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Enterprise value to revenue forward of Pasithea Therapeutics Corp. – NASDAQ:KTTA - TradingView
Price to book forward of Pasithea Therapeutics Corp. – NASDAQ:KTTA - TradingView
Pasithea Therapeutics Company Profile & Introduction - Moomoo
Enterprise value to revenue forward of Pasithea Therapeutics Corp. – BOATS:KTTAW - TradingView
Price to earnings forward of Pasithea Therapeutics Corp. – BOATS:KTTAW - TradingView
Price to sales forward of Pasithea Therapeutics Corp. – BOATS:KTTAW - TradingView
Pasithea Therapeutics Corp. Actuals & Estimates (NASDAQ:KTTA) - TradingView
KTTA Forecast — Price Target — Prediction for 2027 - TradingView
Pasithea Therapeutics Corp. Financial Disclosures & SEC Filings - TradingView
Form 13G Pasithea Therapeutics Corp. For: 23 June By Investing.com - Investing.com South Africa
Stonepine Group reports 5.8% stake in Pasithea Therapeutics (KTTA) - Stock Titan
Major Investor Quietly Boosts Stake in Pasithea Therapeutics - TipRanks
Coastlands Capital LP acquires $53,000 of Pasithea stock - Investing.com UK
Coastlands Capital LP acquires $53,000 of Pasithea stock By Investing.com - Investing.com Australia
Form 4 Pasithea Therapeutics Corp For: 22 June By Investing.com - Investing.com Nigeria
Coastlands Capital LP (KTTA) adds 100,000 Pasithea Therapeutics shares in open-market buy - Stock Titan
Pasithea Therapeutics Corp (KTTA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pasithea Therapeutics Corp (KTTA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pasithea Therapeutics Corp (KTTA) Institutional Confidence - TradingKey
Pasithea Therapeutics Corp (KTTA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pasithea Therapeutics Corp (KTTA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pasithea Therapeutics Corp (KTTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pasithea Therapeutics Corp (KTTA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pasithea Therapeutics Corp (KTTA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pasithea Therapeutics Corp (KTTAW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pasithea Therapeutics Corp (KTTAW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pasithea Therapeutics Corp (KTTAW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pasithea Therapeutics Corp (KTTAW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pasithea Therapeutics Corp (KTTAW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pasithea Therapeutics Corp (KTTAW) Institutional Confidence - TradingKey
Pasithea Therapeutics Corp (KTTAW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Analysts Are Bullish on Top Healthcare Stocks: Pasithea Therapeutics Corp (KTTA), Adaptive Biotechnologies (ADPT) - The Globe and Mail
Pasithea Therapeutics Corp (KTTAW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pasithea Therapeutics Corp - TradingKey
Pasithea Therapeutics Corp (KTTA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
KTTA Reiterates by HC Wainwright & Co. -- Price Target Maintained at $3.00 - GuruFocus
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial - Investing News Network
Pasithea amends phase 1/1b trial protocol for PAS-004 in NF1 - Investing.com UK
Pasithea Therapeuticson Track to Release I - Moomoo
Pasithea expands PAS-004 clinical trial protocol - grafa.com
Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conference - Investing News Network
Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference - The Manila Times
Pasithea Therapeutics Corp (KTTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Pasithea Therapeutics Corp 주식 (KTTA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| STEINMAN LAWRENCE | Director |
Nov 28 '25 |
Buy |
0.75 |
133,333 |
100,000 |
199,691 |
| Marques Tiago | Chief Executive Officer |
Nov 28 '25 |
Buy |
0.75 |
33,333 |
25,000 |
73,334 |
| Dumesnil Simon | Director |
Nov 28 '25 |
Buy |
0.75 |
33,333 |
25,000 |
35,833 |
1.38%
3.59%
자본화:
|
볼륨(24시간):